Introduction: Lung cancer is the leading cause of cancer mortality worldwide; therefore, understanding the biological or clinical role of tumor-associated antigens and autoantibodies is of eminent interest for designing antitumor immunotherapeutic strategies.
Introduction
Lung cancer is the leading cause of mortality among malignant diseases, with a 5-year survival rate of 5% to 15%. Worldwide, it remains the most common type of *Corresponding author.
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malignancy in men, with the highest incidence in central and Eastern Europe (53.5 in 100,000). 1 With the number of new lung cancer cases rising every year by 3%, smoking of tobacco products is the main risk factor responsible for up to 90% of new carcinomas diagnosed. The link between smoking and lung cancer was shown in 1950, 2 and since then the role of smoking in carcinogenesis has been well established. 3 Cigarette smoke contains a multitude of toxic compounds 4 that can directly activate oncogenes or cause epigenetic changes to the genome. Smoking further contributes to tumorpromoting inflammation, impairs mucociliary clearance, or hampers the immune system. 5 Most cases of lung cancer (80%-85%) are NSCLC, which encompasses three histological subtypes: adenocarcinoma (AC), squamous cell carcinoma (SCC), and large cell carcinoma (5%). The ratio of the different histological subtypes of NSCLC has changed over the years from squamous cell carcinoma (which now accounts for approximately 30% of cases) to adenocarcinoma now being the most prevalent histological subtype (50% of cases). The remaining 15% to 20% of lung cancer cases are attributed to small cell carcinoma. An estimated 10% to 25% of lung cancers worldwide occur in never-smokers (i.e., individuals who have smoked fewer than 100 cigarettes in their lifetime). 6 Lung cancer in never-smokers encompasses mainly adenocarcinoma and occurs with higher frequency in women than in men (in Asia > in North America > in Europe). However, the mortality rates in women and men are similar. SCLC is very rare in neversmokers. The important determining factors for nonsmoking-associated lung cancer include hereditary risks, secondhand smoking, air pollution, ionizing radiation, preexisting lung disease, diet, and hormonal changes. 6, 7 In general, the incidence and mortality of cancer remain high; therefore, there is an urgent need to detect early stages of the disease or monitor relapses after antitumor therapy. Serological detection of autoantibodies against tumor-specific or tumor-associated antigens represents an easy tool not only to identify diagnostic and prognostic markers but also to evaluate immune response to therapy in patients with cancer. 8 The most frequently analyzed humoral responses are against the antigens p53; mucin 1, cell surface associated; c-myc; New York esophageal squamous cell carcinoma 1 (NY-ESO-1); survivin; p62; human epidermal growth factor 2/neu (HER2/neu); and cyclin B1. 9 To date, however, the clinical value of these autoantibodies in malignant diseases remains open to discussion. 8, 9 In lung cancer, the only commercially available autoantibody test consisting of seven antigens (p53, NY-ESO-1, cancer associated gene, GBU4-5, sex determining region Y-box 2, HuD protein and melanomaassociated antigen A4 [MAGE-A4]) has recently been validated in a case-control setting (1613 patients) and may be used as a tool complementary to cancer/testis (CT) antigens for detection of early stages of the disease. 10, 11 However, although this test reached an outstanding 90% specificity, its sensitivity remains relatively low (approximately 41%). 10, 11 Despite controversial results on the autoantibody prognostic or diagnostic values, understanding the characteristics and importance of tumor-specific humoral or cellular immune responses remains a prerequisite for the development of cancer detection and immunotherapeutic strategies.
In our previous unpublished study we observed that a history of active smoking correlated significantly with the frequencies of HER2/neu, NY-ESO-1, and MAGE-A4 tumor antigen-specific antibodies in the serum of patients with NSCLC (n ¼ 32). The frequency of all three tumor-specific antibodies was higher in smokers and declined sharply in the groups of ex-smokers and nonsmokers. On the basis of these preliminary data, we designed a prospective case-control study to compare the frequencies of HER2/neu, NY-ESO-1, and MAGE-A4 tumor antigen-specific antibodies and the corresponding antigen expression in tumoral and nontumoral tissue in two independent cohorts of 121 patients with NSCLC (cohort I [n ¼ 57] and (cohort II [n ¼ 64]) and in an agematched group of cancer-free patients (n ¼ 57). We further evaluated the frequencies of autoantibodies and antigen expression in correlation with smoking history, sex, histological subtype, tumor grade, and stage of disease in patients with NSCLC.
Materials and Methods

Study Population
Peripheral blood was obtained from 57 patients undergoing an operation for NSCLC at the University Hospital Motol in Prague between October 2009 and March 2012 (cohort I). All patients with NSCLC were as far as possible individually matched by sex, age, and smoking history to a control individual with no previous history of a malignant disease, each with no sign of malignancy on a chest radiograph. 
qPCR Analysis of Antigen Expression
Total RNA was isolated from cell lysates using the RNeasy mini kit (Qiagen, Hilden, Germany). The RLT lysis buffer (Qiagen) contained 1% b-mercaptoethanol, and the extraction was performed in accordance with the manufacturer's protocol, including a DNA digestion step. The RNA concentration and purity was determined with a Nanodrop 2000c spectrophotometer (Fisher Thermo Scientific, Waltham, MA). Reverse trancription was performed from 1 mg of total RNA using an iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). The probes were designed, synthetized, and approved by TIB Molbiol Syntheselabor GmBh (Berlin, Germany). Their sensitivity was tested previously in a study by Kloudova et al. 12 Expression of HER2/neu, NY-ESO-1, and MAGE-A4 was determined by quantitative PCR (qPCR) on a CFX96 Touch Real-Time PCR Detection System (BioRad). Each 10 ml of reaction mixture contained 5 ml of KAPA PROBE FAST qPCR Master Mix (Kapa Biosystems, Wilmington, MA), 0.5 mM each of forward and reverse primers (TIB Molbiol), 0.2 mM of TaqMan probe (TIB Molbiol), 1.5 ml of DNase-free water, and 2 ml of 10Â diluted complementary DNA. Each reaction was done in duplicate. The reaction thermal protocol was as follows: 3 minutes at 95 C followed by 45 cycles of amplification (at 95 C for 15 seconds and 60 C for 60 seconds). The formation of PCR products of the expected lengths was confirmed by agarose gel electrophoresis. The quantification cycle values were determined by using CFX Manager software (BioRad), and the relative levels of expression of the studied genes were calculated with GenEx software (MultiD Analyses, Göteborg, Sweden) with the cutoff at the 36th cycle. The cutoff for positive expression was set to relative expression values greater than the mean plus two SDs of the control nontumoral tissue sample.
ELISA
The presence of antibodies against the three tumor antigens HER2/neu, NY-ESO-1, and MAGE-A4 in serum of patients with NSCLC and controls was detected by ELISA as adopted from Gnjatic et al., 13 Long et al., 14 and Stockert et al. 15 The recombinant proteins NY-ESO-1, HER-2/neu, and MAGE-A4 (Origene) were diluted in carbonate coating buffer (Invitrogen, Carlsbad, CA) to a final concentration of 1 mg/mL and coated to 96-well plates overnight at 4 C. Plates were blocked for 1 hour with Assay Buffer (Invitrogen). Human sera diluted to 1:100 and 1:200 were incubated in the antigen-coated wells for 2 hours. Plates were then incubated with secondary antibody (goat polyclonal antibody to human IgG [Abcam, Cambridge, United Kingdom]) for 1 hour. Tetramethylbenzidine substrate (Invitrogen) was added and incubated for 20 minutes. The reaction was stopped by adding Stop Solution (Invitrogen). Plates were immediately read with absorbance at 450 nm. As a positive control, the cytomegalovirus glycoprotein B protein was used. 
Data Evaluation
Serum samples from 57 patients with NSCLC and 57 controls were analyzed by ELISA for the presence of NY-ESO-1, HER-2/neu, and MAGE-A4 autoantibodies. The new unthawed batch of serum samples from 57 control patients was reanalyzed for the presence of NY-ESO-1 antibodies, as were serum samples from cohort II (64 patients with NSCLC). The cutoff point of positive seroreactivity was defined as an optical density value greater than the mean plus two SDs of the controls. The patients with NSCLC and controls were divided into three groups-smokers, ex-smokers, and nonsmokersand evaluated for seropositivity. Ex-smokers were defined as former smokers with at least a 1-year abstinence from smoking. 6 Samples from patients with NSCLC and controls for the assay were interspersed in the order in which the samples were assayed so that any batch effects would be spread over all sample types.
Statistical Methods
Pearson's chi-square test for cross-tables was used to compare frequencies in the groups according to the levels of studied factors (the zero hypothesis being that there is no statistical dependence between the studied factors, with the hypothesis refused for p values less than 0.05, as a result of which the dependency of factors is demonstrated). Pearson's chi-square test of good fit was used to compare frequencies in individual subgroups of the control group compared with the group of patients with cancer. The two-sample t test or its modification with separate variance estimates when the assumption of homogeneity of variance has been violated was used to evaluate the dependence of the average tumor marker level (continuous variables) on the seropositivity of specific antitumor antibodies (the zero hypothesis being that the average tumor marker level is equal in both groups, with the hypothesis refused for p < 0.05, as a result of which a difference in average levels is demonstrated). Data analysis was performed using StatSoft STATISTICA software (version 12) (StatSoft Inc., Tulsa, OK). Relative gene expression levels were calculated by using the DDCt method and normalized to the expression levels of b-actin, with the values given in log2 scale. The graphs in Figure 1 were generated in GraphPad PRISM 6 (GraphPad Software, La Jolla, CA). Table 1 . Patients with NSCLC were distinguished from controls by a panel of tumor markers (CEA, TPA, NSE, SCC, and CYFRA 21-1) (data not shown). A statistically higher level of CYFRA 21-1 (p ¼ 0.008) was detected in the NSCLC group according to a paired t test with a separate variance estimate. An average level of 4.69 ± 4.87 ng/mL in patients with NSCLC versus an average level of 1.86 ± 1.33 ng/mL in control patients was detected. No statistically significant difference between patients with NSCLC and the controls according to the average values of CEA, TPA, NSE, and SCC was found for other tumor markers. 16 No statistically significant difference in age and years of smoking abstinence was found between the group of all patients with NSCLC (n ¼ 121) and the control cancer-free group (n ¼ 57) ( Table 1 ). The range of years of smoking abstinence in the group of ex-smokers (n ¼ 34) was 2 to 40 years, with a median of 13.5 years. However, in nonsmoking patients in both cohorts, we found that significantly more women First, we evaluated the frequency of autoantibodies against NY-ESO-1, HER2/neu, and MAGE-A4 in cohort I (n ¼ 57 patients with NSCLC) and the controls (n ¼ 57). Only antibodies to NY-ESO-1, but not antibodies to HER2/neu and MAGE-A4, were significantly increased in 26.3% of patients with NSCLC (15 of 57) versus in 3.5% of the control group (two of 57) ( Table 4 ). We also found that significantly higher NY-ESO-1 seropositivity was detected in patients with NSCLC with an active smoking history ( Table 4 ). As this is the first report on the prevalence of NY-ESO-1 antibodies in patients with NSCLC with an active smoking history, we decided to validate our results in a second cohort (cohort II) (n ¼ 64 patients with NSCLC). NY-ESO-1 autoantibodies were significantly increased in 14% of the patients with NSCLC from cohort II (nine of 64) versus in the reanalyzed samples of 1.8% of the control group (one of 57) ( Table 4 ). In total, 19.8% of patients with NSCLC (24 of 121) tested positive for NY-ESO-1 antibodies. Because of the low number of NY-ESO-1-seropositive patients in cohort II (seven smokers, two ex-smokers, and no nonsmokers), we were not able to detect a significant correlation with an active smoking history. Statistical evaluation of NY-ESO-1-seropositive smokers from the total 121 patients with NSCLC (cohort I þ cohort II), however, confirmed that the presence of NY-ESO-1 autoantibodies positively correlates with an active smoking history in patients with NSCLC. Of 65 smokers with NSCLC, 27.7% (18 of 65) were NY-ESO-1-positive in contrast to 17.6% of ex-smokers (six of 34) and 0% of nonsmokers (none of 19) (Fig. 1A) . We did not detect any significant difference between pack-years in seven of 64 NY-ESO-1-seropositive smokers (31% ± 17.7%) and 28 of 64 NY-ESO-1-seronegative smokers (31.5% ± 14.5%). We did not detect any correlation among NY-ESO-1 seropositivity, sex, or stage of the disease in patients with NSCLC (data not shown) or AC versus SCC. Interestingly, despite the small number of patients with other histological diagnoses (three patients with large cell carcinoma and three patients with anaplastic carcinoma in cohort I), this group of patients contributed significantly (five of six) to NY-ESO-1 antibody production.
Results
Clinicopathological Characteristics of Patients
with NSCLC and Their Correlation with Patients' Smoking History Clinicopathological characteristics of cohort I (serum samples [n ¼ 57]) and cohort II (serum and tumoral and nontumoral tissue samples [n ¼ 64]) of patients with NSCLC and control patients with no history of malignant disease are summarized in14 of 19 ([73.7%]) than men (five of 19 [26.3%]) have lung cancer (
NY-ESO-1, HER2/neu, and MAGE-A4 Expression in NSCLC Tumors and Their Correlation with Smoking History, Histological Subtype, and Sex
We further analyzed NY-ESO-1, HER2/neu, and MAGE-A4 antigen expression by using qPCR from primary tumor and nontumoral tissue samples (Fig. 1B) . We detected a statistically significantly higher expression of NY-ESO-1 in 6.3% of patients (four of 64) and MAGE-A4 in 35.1% of patients with SCC (20 of 57) than in patients with AC (Table 5 ). Only the expression of MAGE-A4 was strongly associated with a history of smoking and male sex (45.5% of men as opposed to 19.2% of women) ( Table 5 ). All NY-ESO-1-positive tumors (n ¼ 4) were from male patients. However, smoking was not found to be a confounding factor even though there were more nonsmokers among women. HER2/neu antigen was overexpressed in 11.9% of patients with NSCLC (five of 42) when compared with nontumoral tissue, and it was not correlated with any other clinicopathological parameter tested (Table 5 .) We did not observe any significant differences among expression of antigens and tumor grade or stage of the disease. 
Discussion
In this study we compared the frequencies of NY-ESO-1, Her2/neu, and MAGE-A4 antibodies and the antigen expression in tumors of patients with NSCLC and controls with respect to smoking history. Moreover, the frequencies of these antibodies and antigen expression levels were correlated with histologic subtype, sex, and grade and stage of the disease.
We detected significantly higher frequencies of NY-ESO-1 antibodies, but not HER2/neu and MAGE-A4 antibodies, in patients with NSCLC than in the cancer-free control patients. We found that frequencies of specific Table 4 . Seropositivity of Antibodies against NY-ESO-1, HER2/neu, and MAGE-A4
Group of Patients with NSCLC NSCLC Controls
Significance Level
Group of patients with NSCLC Smoker Ex-smoker Nonsmoker
Significance level
Note: Boldface indicates statisically significant p values. NY-ESO-1, New York esophageal squamous cell carcinoma 1; HER2, human epidermal growth factor 2; MAGE-A4, melanoma-associated antigen A4.
antibodies against NY-ESO-1 (19.8% [n ¼ 24]) detected in our study in 121 patients with NSCLC were comparable with the frequencies of 20% and 23% for NY-ESO-1 that were reported in the two previous lung cancer studies. 17, 18 We detected NY-ESO-1 mRNA expression in 6% (four of 64), Her2/neu in 11.9% (five of 42), and MAGE-A4 in 35% (20 of 57) of patients with NSCLC. The published frequencies for these antigens in NSCLC are similar, ranging from 2% to 32% for NY-ESO-1, [19] [20] [21] [22] [23] [24] 13% to 35% for MAGE-A4, 19, 20, 22, 23 and 3% to 10% for Her2/ neu. 25, 26 A positive correlation between NY-ESO-1 mRNA expression in tumors and the presence of NY-ESO-1 autoantibodies was detected in only 5% of patients (two of 40) for whom serum and tumor analyses were done in parallel. No NY-ESO-1 mRNA expression was detected in remaining three NY-ESO-1-seropositive patients with available tumor samples. It has been shown that also in high NY-ESO-1-expressing cancers such as ovarian carcinoma or melanoma 5% to 15% of patients have no detectable level of NY-ESO-1 expression in tumor cells despite NY-ESO-1 seropositivity. 15, 27, 28 However, because of the low number of seropositive samples analyzed in our study, it would be highly speculative to draw any conclusions.
NY-ESO-1 antibodies were found to be present at higher frequencies in patients with SCC than in those with AC, 18 but we could not confirm this observation. The same study reported more frequent detection of NY-ESO-1 autoantibodies in undifferentiated tumors (40%) compared with in SCC and AC. 18 Here in a small group of patients with large cell carcinoma and anaplastic carcinoma, we observed a significant contribution to NY-ESO-1 antibody production (in five of six) among patients with NSCLC (15 NY-ESO-1-seropositive patients in total). Whether NY-ESO-1 is preferentially expressed in NSCLC subtypes other than SCC and AC or in undifferentiated tumors needs to be determined in a larger group of patients.
The correlation of the frequency of autoantibodies and smoking history revealed a significantly higher frequency of NY-ESO-1 antibodies in those patients with NSCLC who were active smokers than in patients with NSCLC who were ex-smokers or nonsmokers when compared with the control group. In two studies a significant association of CT antigen expression with smoking history was found, 20, 22 but the production of NY-ESO-1 antibodies that might be induced by smoking has not been previously described. Autoantibody production in smokers, together with antigen expression in tumors, might indicate a chronic inflammatory state in premalignant lesions that is induced by smoking and potentiates the development of tumor-specific immune responses. This would be supported by our observation that nonsmokers displayed neither antibodies nor tumor-specific expression of NY-ESO-1, MAGE-A4, or HER2/neu antigens. Smoking, however, is likely to serve as an important cofactor, rather than as the primary inducer, of other molecular changes that determine NSCLC carcinogenesis, as lung cancer does not develop in all the smokers in their lifetime. The New York esophageal squamous cell carcinoma 1 gene (NY-ESO-1) is located on the X chromosome together with genes coding some other CT antigens. 29 Cancer/testis X-linked genes have been shown to be regulated by demethylation of critical CpG residues within their promoter regions. 30 The expression of NY-ESO-1 could be upregulated by using demethylating agents such as decitabine. 31 Chemicals in cigarette smoke have been shown to induce epigenetic changes in DNA 4, 5 ; therefore, it could be speculated that a similar mechanism might contribute to coordinated expression of CT antigens. 20 MAGE-A4 might be coordinately expressed with NY-ESO-1, as we found its strong correlation with smoking. MAGE-A4 was expressed mainly in men in our study, which has been previously reported. 22, 32 Higher expression of CT antigens was observed in SCC, 20, 24 and this NSCLC subtype has been connected almost exclusively with a history of smoking. In our study we observed that 94.7% of nonsmoking patients have AC, of whom 73.7% were women. This is in agreement with the previous studies on lung cancer in neversmokers. 6 Cigarette smoking is the predominant risk factor not only for lung cancer but also for chronic obstructive pulmonary disease (COPD). 3 In industrialized countries smoking accounts for 95% of COPD cases. 33 Approximately 30% of patients with COPD have been reported to die from lung cancer. 34 Unfortunately, we have no data on the incidence of COPD among our patients, but it would be of interest to determine whether the presence of NY-ESO-1 autoantibodies in patients with COPD would be predictive of the development of lung cancer. The biological role of NY-ESO-1 during carcinogenesis is not known 28, 29 ; however, it has been shown to interact with MAGE-C1 antigen. 35 The MAGE family members were shown to be involved in regulation of apoptosis or cell cycle progression. 36 Of note, MAGE-A4 protein was suggested to act as a tumor suppressor during early stages of carcinogenesis, 37 sensitizing cancer cells to apoptotic stimuli such as chemotherapeutic agents. 38 Interestingly, the expression of NY-ESO-1 and MAGE-A4 in tumors was shown to correlate with a poor prognosis in patients with NSCLC 20, 23, 39 despite NY-ESO-1 immunogenicity and a proapoptotic role of MAGE-A4. NY-ESO-1 was shown to be one of the most immunogenic tumor antigens, 28, 29 as the average autoantibody frequency against single antigens in unselected patients with tumors rarely exceeds 15%. 9 High frequencies of NY-ESO-1 antibodies have also been detected in many other types of cancers together with NY-ESO-1-specific CD8-positive and CD4-positive T cells. 40 The high frequency of humoral and cell-mediated responses gave a rationale for using NY-ESO-1 as a target for cancer vaccines.
28,29
Conclusion
In summary, we have shown here for the first time that autoantibodies against the CT antigen NY-ESO-1 correlate with smoking history in patients with NSCLC, which suggests that smoking-related chronic inflammation might induce the development of NY-ESO-1-specific immune responses. We have also observed that tumor-associated expression of MAGE-A4 correlated with a smoking history, which might suggest its role in early stages of NSCLC development. Because the tumorassociated expression of both NY-ESO-1 and MAGE-A4 were reported to be in an inverse correlation with survival in advanced stages of the disease, 20, 23, 39 the clinical relevance and immunotherapeutic value of our findings remain to be determined.
